CORD-19:775b90287b44353bee979abb0970a4666022f86d / 752966-753466
Annnotations
{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/775b90287b44353bee979abb0970a4666022f86d","sourcedb":"CORD-19","sourceid":"775b90287b44353bee979abb0970a4666022f86d","text":"In this open labeled 16 week trial, 60 adult patients with symptomatic Severe Chronic Idiopathic Urticaria using Cetirizine, 10 mg orally QD, were randomized to continue the existing therapy Cetirizine or to add on Sulfasalazine 500 mg oral tablets (increased by 500mg weekly) until control of clinical symptoms occurred or until reaching a maintenance dose according to patient's weight, 30 to 50 mg/kg per day, in 2 evenly divided doses, not to exceed 2g per day to the existing therapy Cetirizine.","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"T48408","span":{"begin":0,"end":500},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T48408","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T204","span":{"begin":0,"end":500},"obj":"Sentence"}],"attributes":[{"subj":"T204","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T5702","span":{"begin":78,"end":106},"obj":"Disease"},{"id":"T5703","span":{"begin":86,"end":106},"obj":"Disease"},{"id":"T59536","span":{"begin":78,"end":106},"obj":"Disease"},{"id":"T61913","span":{"begin":86,"end":106},"obj":"Disease"}],"attributes":[{"id":"A5702","pred":"mondo_id","subj":"T5702","obj":"http://purl.obolibrary.org/obo/MONDO_0044212"},{"id":"A5703","pred":"mondo_id","subj":"T5703","obj":"http://purl.obolibrary.org/obo/MONDO_0044211"},{"id":"A21888","pred":"mondo_id","subj":"T59536","obj":"http://purl.obolibrary.org/obo/MONDO_0044212"},{"id":"A15864","pred":"mondo_id","subj":"T61913","obj":"http://purl.obolibrary.org/obo/MONDO_0044211"},{"subj":"T5702","pred":"source","obj":"CORD-19-PD-MONDO"},{"subj":"T5703","pred":"source","obj":"CORD-19-PD-MONDO"},{"subj":"T59536","pred":"source","obj":"CORD-19-PD-MONDO"},{"subj":"T61913","pred":"source","obj":"CORD-19-PD-MONDO"}]},{"project":"CORD-19-PD-HP","denotations":[{"id":"T4002","span":{"begin":78,"end":106},"obj":"Phenotype"},{"id":"T4003","span":{"begin":97,"end":106},"obj":"Phenotype"}],"attributes":[{"id":"A4002","pred":"hp_id","subj":"T4002","obj":"http://purl.obolibrary.org/obo/HP_0410133"},{"id":"A4003","pred":"hp_id","subj":"T4003","obj":"http://purl.obolibrary.org/obo/HP_0001025"},{"subj":"T4002","pred":"source","obj":"CORD-19-PD-HP"},{"subj":"T4003","pred":"source","obj":"CORD-19-PD-HP"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#c1ec93","default":true},{"id":"CORD-19_Custom_license_subset","color":"#ec93db"},{"id":"CORD-19-PD-MONDO","color":"#93ece3"},{"id":"CORD-19-PD-HP","color":"#ecc993"}]}]}}